Lundbeck

Lundbeck to Acquire Longboard Pharmaceuticals

Danish drugmaker Lundbeck has announced to acquire US company Longboard Pharmaceuticals in a deal valued at approximately $2.6 billion. Longboard, headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases.

Artificial Intelligence for New Drug Design

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.

Lundbeck to Acquire Prexton Therapeutics

iBIO and iBIO Institute Boards Elect Andy Hull and Linda Friedman as 2014 Chairs

China to Launch Fresh Pharmaceutical Bribery Probe

Lundbeck Suffers Q2 Loss

Lundbeck, Merck KGaA and Others Fined for Blocking Rival Drugs

EU to Fine Lundbeck, Others for Blocking Generic Drugs

Drugmakers, Academics Pool R&D in $265 Million EU Project

Lundbeck's Alcohol Dependency Drug Gets EU Green Light

Lundbeck in Deal with Teva over Copycat Antidepressant

EU to Charge Servier, Lundbeck over Generics

EU Puts Squeeze On Drug Supplies For U.S. Executions

Lundbeck Buys Neuronicon Danish pharmaceuticals group